Drug Profile
Research programme: combination therapies - Pharnext-Tasly JV
Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Pharnext - Tasly (JV)
- Class Antineoplastics; Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for research development in Cancer in Unknown
- 28 Jun 2021 No recent reports of development identified for research development in Cardiovascular-disorders in Unknown
- 10 May 2017 Early research in Cardiovascular disorders and Cancer (unspecified route)